About Editas Medicine
Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
Headquarters
Editas Medicine, Cambridge
Founded
2013-01-01
Industry
Biotechnology, Genetics, Health Care, Medical
Last Funding Type
Post Ipo Equity
Valuation
1
Total Funding
$931.60 million dollars
IPO Status
Public
Financial
Editas Medicine reported improved financials and advances in gene editing trials. However, the company has also experienced significant financial contraction, with shareholders enduring an 87% loss over the past three years and a 90% loss for some investors. The first quarter of 2024 earnings missed expectations, and consensus forecasts have become darker since the latest report. Despite these challenges, Editas Medicine outlined strategic pillars for 2024 and remains a favorite among institutional investors, who own 71% of the company.
Editas Medicine reported a quarterly loss of $0.76 per share, missing the Zacks Consensus Estimate of a loss of $0.63. Revenue for Q1 2024 was $1.14 million, down 89% from the previous year. The company also announced positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease. Additionally, a high-ranking executive sold over 22,000 shares of the company.
Editas Medicine reported a quarterly loss of $0.76 per share, missing the Zacks Consensus Estimate of a loss of $0.63. Revenue for Q1 2024 was $1.14 million, down 89% from the previous year. The company also announced positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease. Additionally, a high-ranking executive sold over 22,000 shares of the company.
Funding Rounds
7
Number of Lead Investors
5
Total Funding Amount
$931.60 million dollars
Number of Investors
19